Kinetics of an Intravenously Injected Fat Emulsion Reflect Postheparin Plasma Lipoprotein Lipase Mass and Activity

Sakuma, Nagahiko; Ikeuchi, Reiko; Hibino, Takeshi; Ohte, Nobuyuki; Tamai, Nozomu; Kamiya, Tetsuro; Kimura, Genjirou

doi:10.3164/jcbn.31.37

Cited by 1 publication

(2 citation statements)

References 34 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 Previously, we reported a significant correlation between K 2 and postheparin plasma LPL mass and activity. 13 In the current study, the K 2 value and LPL mass and activity in postheparin plasma increased. From these results, it is supposed that TG-rich lipoprotein catabolism is accelerated, resulting in increased production of HDL 3 by bezafibrate administration.…”

Section: Discussionmentioning

confidence: 87%

“…11,12 The K 2 value has been shown to correlate closely with LPL mass and LPL activity in postheparin plasma. 13 We previously reported that bezafibrate {propanoic acid (2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl)}, a derivative of clofibrate that improves lipid metabolism, accelerates clearance of TG-rich lipoprotein, thereby lowering serum TG and elevating HDL-C. 14 In the present study, the effects of bezafibrate on K 2 , HDL 3 -C, and HDL 2 -C were assessed in patients with primary hypertriglyceridemia.…”

Section: Hypertriglyceridemia Accompanied By Low Levels Of High-densimentioning

confidence: 99%

See 1 more Smart Citation

Increased serum triglyceride clearance and elevated high-density lipoprotein 2 and 3 cholesterol during treatment of primary hypertriglyceridemia with bezafibrate

Sakuma

Ikeuchi²,

Hibino

et al. 2003

Current Therapeutic Research

Self Cite

View full text Add to dashboard Cite

Background: Hypertriglyceridemia accompanied by low levels of high-density lipoprotein cholesterol (HDL-C) is a risk factor for coronary artery disease. High-density lipoprotein 2 (HDL 2 ) and 3 (HDL 3 ) are believed to suppress the progress of atherosclerosis through reverse cholesterol transport. As a result, peripheral tissues can be protected against excessive accumulation of cholesterol. Although bezafibrate is known to accelerate the increase of HDL-C, results are not standardized regarding increases of HDL 3 and HDL 2 subfractions.Objective: This study assessed the effects of bezafibrate on serum triglyceride (TG) fractional clearance rate (K 2 ) and HDL 2 and HDL 3 cholesterol (HDL 2 -C and HDL 3 -C, respectively) levels in patients with primary hypertriglyceridemia (serum TG Ն150 mg/dL).Methods: Outpatients with primary hypertriglyceridemia were enrolled in this 8-week study conducted at the Third Department of Internal Medicine, Nagoya City University Hospital (Nagoya, Japan). Oral bezafibrate was administered at a dose of 400 mg/d (200-mg tablet BID, morning and evening) for 8 weeks. After 8 weeks, serum levels of total cholesterol (TC), TG, HDL-C, HDL 2 -C, and HDL 3 -C were measured. A fat emulsion tolerance test to assess K 2 and measurements of plasma lipoprotein lipase (LPL) mass, LPL activity, and hepatic triglyceride lipase (HTGL) activity in postheparin plasma were performed before bezafibrate administration and after the course of treatment.Results 697CURRENT THERAPEUTIC RESEARCH study. The following findings were observed in male and female patients after 8 weeks of treatment. A statistically significant reduction was observed in mean serum TG level (P Ͻ 0.01). Significant increases were seen in HDL-C, HDL 2 -C, and HDL 3 -C (all P Ͻ 0.01), K 2 (P Ͻ 0.01), and in plasma LPL mass (P Ͻ 0.01) and LPL activity (P Ͻ 0.05). TC level and HTGL activity did not change significantly.No adverse effects related to the use of bezafibrate were documented. Conclusions: In this study, bezafibrate treatment resulted in significant decreases in serum TG level and significant increases in HDL 2 -C and HDL 3 -C levels and plasma LPL mass and activity. We hypothesize that bezafibrate may increase HDL 3 -C by promoting TG-rich lipoprotein catabolism and may increase HDL 2 -C by promoting the conversion of HDL 3 to HDL 2 . (Curr Ther Res Clin Exp. 2003; 64:697-706)

show abstract

Section: Discussionmentioning

confidence: 87%

Section: Hypertriglyceridemia Accompanied By Low Levels Of High-densimentioning

confidence: 99%

Increased serum triglyceride clearance and elevated high-density lipoprotein 2 and 3 cholesterol during treatment of primary hypertriglyceridemia with bezafibrate

Sakuma

Ikeuchi²,

Hibino

et al. 2003

Current Therapeutic Research

Self Cite

View full text Add to dashboard Cite

show abstract

Kinetics of an Intravenously Injected Fat Emulsion Reflect Postheparin Plasma Lipoprotein Lipase Mass and Activity

Cited by 1 publication

References 34 publications

Increased serum triglyceride clearance and elevated high-density lipoprotein 2 and 3 cholesterol during treatment of primary hypertriglyceridemia with bezafibrate

Increased serum triglyceride clearance and elevated high-density lipoprotein 2 and 3 cholesterol during treatment of primary hypertriglyceridemia with bezafibrate

Contact Info

Product

Resources

About